title: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
abstract: Although postoperative adjuvant chemotherapy (PAC) with uracil-tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy. Therefore, it is extremely important to identify patients for whom adjuvant chemotherapy will be beneficial. We performed comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules. Furthermore, we carried out immunohistochemical studies of 90 adenocarcinoma specimens to validate the results of LC-MS/MS. We detected two kinds of protein molecules (myosin IIA and vimentin) by LC-MS/MS. We confirmed their immunohistochemical expression and distribution, and evaluated the relationship between the expression of these proteins and prognosis after adjuvant chemotherapy. Patients with no expression of either myosin IIA or vimentin showed a significantly better outcome regardless of PAC using uracil-tegafur. However, we were unable to select responders to uracil-tegafur using these proteins. Cases of adenocarcinoma lacking expression of either myosin IIA or vimentin show a good outcome without PAC, and therefore do not require such treatment.
authors.affiliation: Department of Surgery, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Hirano
authors.forename: A
authors.initials: A
authors.lastname: Ogiwara
authors.forename: S
authors.initials: S
authors.lastname: Akimoto
authors.forename: T
authors.initials: T
authors.lastname: Kawakami
authors.forename: Y
authors.initials: Y
authors.lastname: Fukui
authors.forename: T
authors.initials: T
authors.lastname: Oka
authors.forename: Y
authors.initials: Y
authors.lastname: Gong
authors.forename: R
authors.initials: R
authors.lastname: Guo
authors.forename: H
authors.initials: H
authors.lastname: Inada
authors.forename: K
authors.initials: K
authors.lastname: Nawa
authors.forename: M
authors.initials: M
authors.lastname: Kojika
authors.forename: Y
authors.initials: Y
authors.lastname: Suga
authors.forename: T
authors.initials: T
authors.lastname: Ohira
authors.forename: K
authors.initials: K
authors.lastname: Mukai
authors.forename: H
authors.initials: H
authors.lastname: Kato
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D000284:Administration, Oral; D000595:Amino Acid Sequence; D015415:Biomarkers; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008969:Molecular Sequence Data; D024507:Nonmuscle Myosin Type IIA / Q000032:analysis; D011184:Postoperative Period; D011379:Prognosis; D040901:Proteomics / Q000379:methods; D016019:Survival Analysis; D005641:Tegafur / Q000627:therapeutic use*; D014746:Vimentin / Q000032:analysis
chemical_list: D015415:Biomarkers; D014746:Vimentin; D005641:Tegafur; D024507:Nonmuscle Myosin Type IIA